{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:16:00Z","timestamp":1771931760945,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-026-01985-3","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T04:50:42Z","timestamp":1769748642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["RLIP depletion suppresses ovarian cancer growth and metastasis"],"prefix":"10.1186","volume":"19","author":[{"given":"B. Madhu","family":"Krishna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Horne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prakash","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6415-8160","authenticated-orcid":false,"given":"Sharad S.","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"1985_CR1","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3390\/cancers17050788","volume":"17","author":"S Choe","year":"2025","unstructured":"Choe S, Jeon M, Yoon H. Advanced therapeutic approaches for metastatic ovarian cancer. Cancers. 2025;17:788.","journal-title":"Cancers"},{"key":"1985_CR2","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics. CA Cancer J Clin. 2025;75:10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"1985_CR3","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"GC Jayson","year":"2014","unstructured":"Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384:1376\u201388.","journal-title":"Lancet"},{"key":"1985_CR4","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41571-023-00819-1","volume":"20","author":"AC Veneziani","year":"2023","unstructured":"Veneziani AC, Gonzalez-Ochoa E, Alqaisi H, Madariaga A, Bhat G, Rouzbahman M, Sneha S, Oza AM. Heterogeneity and treatment landscape of ovarian carcinoma. Nat Rev Clin Oncol. 2023;20:820\u201342.","journal-title":"Nat Rev Clin Oncol"},{"key":"1985_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","volume":"21","author":"PM Webb","year":"2024","unstructured":"Webb PM, Jordan S. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024;21:389\u2013400.","journal-title":"Nat Rev Clin Oncol"},{"key":"1985_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1\u20136.","journal-title":"N Engl J Med"},{"issue":"4","key":"1985_CR7","first-page":"280","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280\u2013304.","journal-title":"CA Cancer J Clin"},{"key":"1985_CR8","doi-asserted-by":"publisher","first-page":"e25976","DOI":"10.2196\/25976","volume":"7","author":"SP Yang","year":"2021","unstructured":"Yang SP, Su HL, Chen XB, Hua L, Chen JX, Hu M, Lei J, Wu S-G, Zhou J. Long-term survival among histological subtypes in advanced epithelial ovarian cancer: population-based study using the surveillance, epidemiology, and end results database. JMIR Public Health Surveill. 2021;7:e25976.","journal-title":"JMIR Public Health Surveill"},{"key":"1985_CR9","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/bjc.2016.311","volume":"115","author":"GE Konecny","year":"2016","unstructured":"Konecny GE, Kristeleit RS. PARP inhibitors for BRCA1\/2-mutated and sporadic ovarian cancer: current practice and future directions. Br J Cancer. 2016;115:1157\u201373.","journal-title":"Br J Cancer"},{"key":"1985_CR10","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/AOG.0b013e318264f794","volume":"120","author":"LA Baldwin","year":"2012","unstructured":"Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, DeSimone CP, Ueland FR, Nagell JRV, Seamon LG. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol. 2012;120:612\u20138.","journal-title":"Obstet Gynecol"},{"key":"1985_CR11","first-page":"2105","volume":"19","author":"CZ Wang","year":"2015","unstructured":"Wang CZ, Yuan P, Xu B, Yuan L, Yang HX, Liu X. RLIP76 expression as a prognostic marker of breast cancer. Eur Rev Med Pharmacol Sci. 2015;19:2105\u201311.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1985_CR12","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/carcin\/bgs401","volume":"34","author":"Q Wang","year":"2013","unstructured":"Wang Q, Wang JY, Zhang XP, Lv ZW, Fu D, Lu YC, et al. RLIP76 is overexpressed in human glioblastomas and is required for proliferation, tumorigenesis and suppression of apoptosis. Carcinogenesis. 2013;34:916\u201326.","journal-title":"Carcinogenesis"},{"key":"1985_CR13","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1593\/neo.101080","volume":"12","author":"Z Wu","year":"2010","unstructured":"Wu Z, Owens C, Chandra N, Popovic K, Conaway M, Theodorescu D. RalBP1 is necessary for metastasis of human cancer cell lines. Neoplasia. 2010;12:1003\u201312.","journal-title":"Neoplasia"},{"key":"1985_CR14","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.bbrc.2014.10.114","volume":"454","author":"S Lee","year":"2014","unstructured":"Lee S, Wurtzel JGT, Goldfinger LE. The RLIP76 N-terminus binds ARNO to regulate PI 3-kinase, Arf6 and Rac signaling, cell spreading and migration. Biochem Biophys Res Commun. 2014;454:560\u20135.","journal-title":"Biochem Biophys Res Commun"},{"key":"1985_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13048-019-0510-8","volume":"12","author":"DH Billhaq","year":"2019","unstructured":"Billhaq DH, Lee S. A potential function of RLIP76 in the ovarian corpus luteum. J Ovarian Res. 2019;12:34.","journal-title":"J Ovarian Res"},{"key":"1985_CR16","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1158\/0008-5472.CAN-12-0468","volume":"72","author":"S Lee","year":"2012","unstructured":"Lee S, Wurtzel J, Singhal SS, Awasthi S, Goldfinger LE. RALBP1\/RLIP76 depletion in mice suppresses tumor growth by inhibiting tumor neo-vascularization. Cancer Res. 2012;72:5165\u201373.","journal-title":"Cancer Res"},{"key":"1985_CR17","doi-asserted-by":"publisher","first-page":"9327","DOI":"10.1021\/bi992964c","volume":"39","author":"S Awasthi","year":"2000","unstructured":"Awasthi S, Cheng J, Singhal SS, Saini MK, Pandya U, Pikula S, et al. Novel function of human RLIP76: atp-dependent transport of glutathione conjugates and doxorubicin. Biochemistry. 2000;39:9327\u201334.","journal-title":"Biochemistry"},{"key":"1985_CR18","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/ijc.11260","volume":"106","author":"S Awasthi","year":"2003","unstructured":"Awasthi S, Singhal SS, Sharma R, Zimniak P, Awasthi YC. Transport of glutathione conjugates and chemotherapeutic drugs by RLIP76 (RALBP1): a novel link between G-protein and tyrosine kinase signaling and drug resistance. Int J Cancer. 2003;106:635\u201346.","journal-title":"Int J Cancer"},{"key":"1985_CR19","doi-asserted-by":"publisher","first-page":"6022","DOI":"10.1158\/0008-5472.CAN-05-0968","volume":"65","author":"S Awasthi","year":"2005","unstructured":"Awasthi S, Singhal SS, Yadav S, Singhal J, Drake K, Nadkar A, Zajac E, Wickrarachchi D, Rowe N, Yacoub A, et al. RLIP76 is a major determinant of radiation sensitivity. Cancer Res. 2005;65:6022\u20138.","journal-title":"Cancer Res"},{"key":"1985_CR20","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1158\/1078-0432.CCR-08-0145","volume":"14","author":"S Awasthi","year":"2008","unstructured":"Awasthi S, Singhal SS, Awasthi YC, Martin B, Woo J-H, Cunningham C, Frankel AE. RLIP76 and cancer. Clin Cancer Res. 2008;14:4372\u20137.","journal-title":"Clin Cancer Res"},{"key":"1985_CR21","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1158\/0008-5472.CAN-05-3534","volume":"66","author":"SS Singhal","year":"2006","unstructured":"Singhal SS, Awasthi YC, Awasthi S. Regression of melanoma in a murine model by RLIP76 depletion. Cancer Res. 2006;66:2354\u201360.","journal-title":"Cancer Res"},{"key":"1985_CR22","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1158\/0008-5472.991.65.3","volume":"65","author":"D Stuckler","year":"2005","unstructured":"Stuckler D, Singhal J, Singhal SS, Yadav S, Awasthi YC, Awasthi S. RLIP76 transports Vinorelbine and mediates drug resistance in non-small cell lung cancer. Cancer Res. 2005;65:991\u20138.","journal-title":"Cancer Res"},{"key":"1985_CR23","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.1158\/0008-5472.CAN-06-4124","volume":"67","author":"SS Singhal","year":"2007","unstructured":"Singhal SS, Singhal J, Yadav S, Dwivedi S, Boor PJ, Awasthi YC, et al. Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1). Cancer Res. 2007;67:4382\u20139.","journal-title":"Cancer Res"},{"key":"1985_CR24","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.1158\/0008-5472.CAN-08-3521","volume":"69","author":"SS Singhal","year":"2009","unstructured":"Singhal SS, Singhal J, Yadav S, Sahu M, Awasthi YC, Awasthi S. RLIP76: a target for kidney cancer therapy. Cancer Res. 2009;69:4244\u201351.","journal-title":"Cancer Res"},{"key":"1985_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115847","volume":"217","author":"S Ramisetty","year":"2023","unstructured":"Ramisetty S, Garg P, Mohanty A, Mirzapoiazova T, Yue E, Wang E, et al. Regression of ovarian cancer xenografts by depleting or inhibiting RLIP. Biochem Pharmacol. 2023;217:115847.","journal-title":"Biochem Pharmacol"},{"key":"1985_CR26","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/carcin\/bgae047","volume":"45","author":"BM Krishna","year":"2024","unstructured":"Krishna BM, Ramisetty SK, Garg P, Mohanty A, Wang E, Horne D, Awasthi S, Kulkarni P, Salgia R, Singhal SS. Enhancing carboplatin sensitivity in ovarian cancer cells by blocking the mercapturic acid pathway transporter. Carcinogenesis. 2024;45:696\u2013707.","journal-title":"Carcinogenesis"},{"key":"1985_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-025-01740-0","volume":"18","author":"BM Krishna","year":"2025","unstructured":"Krishna BM, Garg P, Kulkarni P, Horne D, Salgia R, Singhal SS. Targeting the oncoprotein RLIP as novel therapy for ovarian cancer. J Ovarian Res. 2025;18:150.","journal-title":"J Ovarian Res"},{"key":"1985_CR28","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.bcp.2008.11.013","volume":"77","author":"SS Singhal","year":"2009","unstructured":"Singhal SS, Roth C, Leake K, Singhal J, Yadav S, Awasthi S. Regression of prostate cancer xenografts by RLIP76 depletion. Biochem Pharmacol. 2009;77:1074\u201383.","journal-title":"Biochem Pharmacol"},{"key":"1985_CR29","first-page":"365","volume":"22","author":"SS Singhal","year":"2003","unstructured":"Singhal SS, Singhal J, Sharma R, Singh SV, Zimniak P, Awasthi YC, et al. Role of RLIP76 in lung cancer doxorubicin resistance: the ATPase activity of RLIP76 correlates with doxorubicin and 4-hydroxynonenal resistance in lung cancer cells. Int J Oncol. 2003;22:365\u201375.","journal-title":"Int J Oncol"},{"key":"1985_CR30","volume":"33","author":"S Sambasivan","year":"2022","unstructured":"Sambasivan S. Epithelial ovarian cancer: review article. Cancer Treat Res Commun. 2022;33:100629.","journal-title":"Cancer Treat Res Commun"},{"key":"1985_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/1535-7163.MCT-10-0699","volume":"10","author":"SS Singhal","year":"2011","unstructured":"Singhal SS, Wickramarachchi D, Yadav S, Singhal J, Leake K, Vatsyayan R, et al. Glutathione-conjugate transport by RLIP76 is required for clathrin-dependent endocytosis and chemical carcinogenesis. Mol Cancer Ther. 2011;10:16\u201328.","journal-title":"Mol Cancer Ther"},{"key":"1985_CR32","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1073\/pnas.1719586115","volume":"115","author":"S Awasthi","year":"2018","unstructured":"Awasthi S, Tompkins J, Singhal J, Riggs AD, Yadav S, Wu X, et al. RLIP depletion prevents spontaneous neoplasia in TP53 null mice. Proc Natl Acad Sci USA. 2018;115:3918\u201323.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-026-01985-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-01985-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-01985-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:29:23Z","timestamp":1771928963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-026-01985-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1985"],"URL":"https:\/\/doi.org\/10.1186\/s13048-026-01985-3","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No human participants were included in the current study. The City of Hope Animal Care and Ethics Committee approved IACUC procedure #22011 for the laboratory animal-related studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}